Home / Resources / Articles / It’s Not Just Insulin: Researchers Find Another Hormone Problem in the Diabetic Pancreas

It’s Not Just Insulin: Researchers Find Another Hormone Problem in the Diabetic Pancreas

Nov 21, 2026
641 views
 

Could a problem with blood sugar control begin with a hormone other than insulin? New research into pancreatic delta cells and diabetes is revealing how another hormone may influence blood sugar control. Scientists have found that these lesser-known cells respond poorly to signals that normally tell them to slow down. The finding sheds light on communication inside the diabetic pancreas, but it does not point to a proven new treatment.

Table of Contents

  • How delta cells help regulate blood sugar
  • What researchers found in type 2 diabetes
  • Why somatostatin feedback matters
  • What this means for diabetes care
  • Conclusion
  • Frequently asked questions

How Pancreatic Delta Cells Help Regulate Blood Sugar

Most discussions of diabetes start with insulin, the hormone that helps lower blood glucose. However, insulin does not work alone. Tiny pancreatic clusters called islets contain several cell types that coordinate hormone release. Beta cells make insulin, while alpha cells release glucagon, which helps raise blood glucose when it falls. Meanwhile, delta cells produce somatostatin, a hormone that helps limit the activity of both neighbors.

 

Think of somatostatin as a volume control rather than an on-off switch. It helps prevent insulin and glucagon signals from continuing longer than needed. Much of this communication happens locally inside each islet. Diabetes in Control interviewed researcher Mark Huising about the role of delta cells in glucose control. As a result, understanding the role of delta cells in diabetes requires looking beyond insulin production alone.

What Researchers Found in Type 2 Diabetes

In a study published in PNAS in November 2026, scientists examined isolated delta cells from deceased donors with and without type 2 diabetes. They used imaging, electrical recordings, and secretion tests to study cell responses. This helped separate each cell's behavior from its neighbors' signals.

In cells from donors without diabetes, somatostatin helped reduce further delta-cell activity. This self-limiting process is called feedback. Adrenaline, also called epinephrine, produced a similar braking effect. However, delta cells from donors with type 2 diabetes were less responsive to these inhibitory signals. The researchers also observed much less of a somatostatin receptor called SSTR2 on the surface of those cells.

Not every response was weakened. For example, higher glucose levels still encouraged somatostatin release, and glucagon or exendin-4 further boosted it in laboratory tests. Insulin did not have a detectable direct effect in these experiments. Together, the findings suggest a selective failure of inhibitory feedback, not a complete loss of delta-cell function.

Why Somatostatin Resistance Matters for Islet Signaling

Delta cells may fail to respond normally to signals to stop. Consequently, their hormone output could become poorly timed or excessive under certain conditions. That matters because somatostatin can restrain both insulin and glucagon release. Too much inhibition at the wrong moment could disrupt the balance that helps keep glucose steady.

This idea also fits with other emerging research. A small 2025 study of human pancreatic islets found greater stimulated somatostatin release from islets donated by people with type 2 diabetes. Still, the studies used different methods, and neither proves that altered delta-cell signaling causes diabetes or explains every person's glucose levels. In living people, nerves, meals, and medicines also affect hormone release.

For now, changes in pancreatic delta-cell function are best understood as one part of the complex biology of diabetes. The new work points toward a possible breakdown in the pancreas's internal feedback system. Nevertheless, a cell-level finding cannot yet tell clinicians whether adjusting somatostatin signaling would help patients safely.

What the Findings Mean for Diabetes Care and Research

For clinicians and people living with diabetes, the immediate message is about biology rather than changing treatment. The study did not test a drug, track long-term blood glucose, or show improved A1C outcomes. Therefore, it provides no reason to stop or switch prescribed medicines. Established approaches to diabetes care remain important, including appropriate medication, glucose monitoring, nutrition, and physical activity.

However, the findings raise useful questions for future research. Why are fewer SSTR2 receptors present on affected delta cells? Does restoring normal feedback improve the timing of insulin and glucagon release in intact human islets? And could researchers target this process without blocking the glucagon response needed during low blood sugar?

Larger studies must test whether this process changes glucose control in living systems. Researchers must also distinguish causes of diabetes from related changes. Meanwhile, readers interested in the wider physiology can explore Diabetes in Control's overview of pancreatic islet hormones. Research into pancreatic delta-cell function could help scientists better understand type 2 diabetes, although these findings have not yet led to a new treatment.

Conclusion

Insulin remains central to diabetes, but it is not the pancreas's only important messenger. New evidence suggests that delta cells in type 2 diabetes may lose sensitivity to the signals that normally limit somatostatin release. As a result, communication between islet cells could become less precise. These findings highlight the need for further research into delta-cell signaling before scientists can determine whether it offers a useful treatment target.

Frequently Asked Questions

1. What are pancreatic delta cells?

Delta cells are hormone-producing cells in pancreatic islets. They release somatostatin, which helps regulate nearby insulin-producing beta cells and glucagon-producing alpha cells.

2. How does somatostatin affect blood sugar?

Somatostatin helps slow insulin and glucagon secretion. Therefore, it influences the timing and balance of hormones involved in controlling blood glucose.

3. Did researchers find a new treatment for type 2 diabetes?

No. The November 2026 study examined cells from human donors, not the benefits of a treatment in patients.

4. Can delta-cell dysfunction explain all cases of type 2 diabetes?

No. Type 2 diabetes involves insulin resistance, changes in insulin production, and other factors. Delta-cell signaling may be one additional piece of that complex picture.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.